Intravenous immunoglobulin in the management of idiopathic inflammatory myositis: A single centre retrospective review
Objective: Intravenous immunoglobulin (IVIG) has been used in the treatment of severe idiopathic inflammatory myositis (IIM) in the past. We conducted a retrospective analysis of IIM cases and compared patients who received IVIG with those who did not. Methods: Electronic records from the year 2015–...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=6;spage=200;epage=204;aulast=Patel |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832544169825927168 |
|---|---|
| author | Jeet Hemantkumar Patel Lalit Duggal Ved Chaturvedi Neeraj Jain Gurbir Bhandari Mayank Gupta |
| author_facet | Jeet Hemantkumar Patel Lalit Duggal Ved Chaturvedi Neeraj Jain Gurbir Bhandari Mayank Gupta |
| author_sort | Jeet Hemantkumar Patel |
| collection | DOAJ |
| description | Objective: Intravenous immunoglobulin (IVIG) has been used in the treatment of severe idiopathic inflammatory myositis (IIM) in the past. We conducted a retrospective analysis of IIM cases and compared patients who received IVIG with those who did not.
Methods: Electronic records from the year 2015–2019 were searched for myositis cases using the terms “myositis, inflammatory myositis, autoimmune myositis.” Cases with dermatomyositis, polymyositis, necrotizing autoimmune myositis, and connective tissue disease myositis/overlap myositis were included (n = 28) and those with infectious or granulomatous myositis were excluded (n = 7). Relevant data were noted. Participants were classified into cases and controls based on IVIG use for treatment. Results were expressed as median and interquartile range. Nonparametric testes were used for comparisons.
Results: Word search revealed 35 cases of myositis. Of them, 28 patients were included in the study. From these patients, ten patients had treatment with IVIG and 18 had not. The median age was 49.5 (39.5, 57) years, and disease duration 5.5 (2.5, 12) months. IVIG-treated patients had a more extended hospital stay and less arthritis (P < 0.05). A common indication of IVIG use was esophageal ± respiratory muscle weakness (n = 5/10). In the IVIG group, there was a higher rate of pulse glucocorticoids use (P = −0.02); however, the use of other drugs was similar. Sepsis, gastrointestinal complications, and pneumonia were higher in IVIG-treated patients (P < 0.05). IVIG-treated patients had a higher mortality rate and lower response compared to controls (P < 0.05).
Conclusion: IVIG is often the drug of choice for patients with infections in IIM in the Indian setting. Although the IVIG group suffered high mortality, confounding factors, and small sample size, limit conclusions on the usefulness of IVIG in IIM. However, this study showed that IVIG might not alleviate infections complicating IIM cases. Further studies are required. |
| format | Article |
| id | doaj-art-f8aaf2bdb40b4e0fad85379d89f22a3c |
| institution | Kabale University |
| issn | 0973-3698 0973-3701 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Indian Journal of Rheumatology |
| spelling | doaj-art-f8aaf2bdb40b4e0fad85379d89f22a3c2025-02-03T10:54:59ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012020-01-0115620020410.4103/injr.injr_28_20Intravenous immunoglobulin in the management of idiopathic inflammatory myositis: A single centre retrospective reviewJeet Hemantkumar PatelLalit DuggalVed ChaturvediNeeraj JainGurbir BhandariMayank GuptaObjective: Intravenous immunoglobulin (IVIG) has been used in the treatment of severe idiopathic inflammatory myositis (IIM) in the past. We conducted a retrospective analysis of IIM cases and compared patients who received IVIG with those who did not. Methods: Electronic records from the year 2015–2019 were searched for myositis cases using the terms “myositis, inflammatory myositis, autoimmune myositis.” Cases with dermatomyositis, polymyositis, necrotizing autoimmune myositis, and connective tissue disease myositis/overlap myositis were included (n = 28) and those with infectious or granulomatous myositis were excluded (n = 7). Relevant data were noted. Participants were classified into cases and controls based on IVIG use for treatment. Results were expressed as median and interquartile range. Nonparametric testes were used for comparisons. Results: Word search revealed 35 cases of myositis. Of them, 28 patients were included in the study. From these patients, ten patients had treatment with IVIG and 18 had not. The median age was 49.5 (39.5, 57) years, and disease duration 5.5 (2.5, 12) months. IVIG-treated patients had a more extended hospital stay and less arthritis (P < 0.05). A common indication of IVIG use was esophageal ± respiratory muscle weakness (n = 5/10). In the IVIG group, there was a higher rate of pulse glucocorticoids use (P = −0.02); however, the use of other drugs was similar. Sepsis, gastrointestinal complications, and pneumonia were higher in IVIG-treated patients (P < 0.05). IVIG-treated patients had a higher mortality rate and lower response compared to controls (P < 0.05). Conclusion: IVIG is often the drug of choice for patients with infections in IIM in the Indian setting. Although the IVIG group suffered high mortality, confounding factors, and small sample size, limit conclusions on the usefulness of IVIG in IIM. However, this study showed that IVIG might not alleviate infections complicating IIM cases. Further studies are required.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=6;spage=200;epage=204;aulast=Patelidiopathic inflammatory myositisinfectionsintravenous immunoglobulin |
| spellingShingle | Jeet Hemantkumar Patel Lalit Duggal Ved Chaturvedi Neeraj Jain Gurbir Bhandari Mayank Gupta Intravenous immunoglobulin in the management of idiopathic inflammatory myositis: A single centre retrospective review Indian Journal of Rheumatology idiopathic inflammatory myositis infections intravenous immunoglobulin |
| title | Intravenous immunoglobulin in the management of idiopathic inflammatory myositis: A single centre retrospective review |
| title_full | Intravenous immunoglobulin in the management of idiopathic inflammatory myositis: A single centre retrospective review |
| title_fullStr | Intravenous immunoglobulin in the management of idiopathic inflammatory myositis: A single centre retrospective review |
| title_full_unstemmed | Intravenous immunoglobulin in the management of idiopathic inflammatory myositis: A single centre retrospective review |
| title_short | Intravenous immunoglobulin in the management of idiopathic inflammatory myositis: A single centre retrospective review |
| title_sort | intravenous immunoglobulin in the management of idiopathic inflammatory myositis a single centre retrospective review |
| topic | idiopathic inflammatory myositis infections intravenous immunoglobulin |
| url | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=6;spage=200;epage=204;aulast=Patel |
| work_keys_str_mv | AT jeethemantkumarpatel intravenousimmunoglobulininthemanagementofidiopathicinflammatorymyositisasinglecentreretrospectivereview AT lalitduggal intravenousimmunoglobulininthemanagementofidiopathicinflammatorymyositisasinglecentreretrospectivereview AT vedchaturvedi intravenousimmunoglobulininthemanagementofidiopathicinflammatorymyositisasinglecentreretrospectivereview AT neerajjain intravenousimmunoglobulininthemanagementofidiopathicinflammatorymyositisasinglecentreretrospectivereview AT gurbirbhandari intravenousimmunoglobulininthemanagementofidiopathicinflammatorymyositisasinglecentreretrospectivereview AT mayankgupta intravenousimmunoglobulininthemanagementofidiopathicinflammatorymyositisasinglecentreretrospectivereview |